Bond.az White LogoBond.az Black Logo

Guggenheim Raises StubHub Target on Strong Q1

Guggenheim lifted StubHub's price target after strong Q1 results, citing revenue and EBITDA beats.

Benjamin Moore
ByBenjamin Moore- Senior Editor
|
0

Guggenheim raised its price target on StubHub Holdings to $8.50 from $7.50, maintaining a Neutral rating.

StubHub reported Q1 revenue of $446 million and adjusted EBITDA of $72 million, beating Guggenheim's estimates of $434 million and $70 million.

The company reaffirmed its 2026 guidance for gross merchandise sales of $9.9-$10.1 billion and adjusted EBITDA of $400-$420 million. Guggenheim raised its estimates accordingly.

StubHub settled with the FTC for $10 million. The UK resale price cap was not included in the King's Speech.

The company continues to reduce leverage, with Guggenheim noting it should reach a comfortable zone by year-end.

More News
Today / 13:34
|
741

Jefferies Reiterates Buy on Biogen Stock

Jefferies reiterates Buy rating on Biogen stock with $210 target following promising Phase II Alzheimer's data.

0
Today / 13:32
|
873

Marvell price target raised to $200 by RBC on optical strength

RBC Capital raised Marvell Technology price target to $200, citing optical business strength. AI networking and custom XPU trends support growth.

0
Today / 13:03
|
769

Morgan Stanley Upgrades Assurant Stock Rating

Morgan Stanley upgrades Assurant stock to Overweight, raises price target to $285. Strong earnings and growth outlook highlighted.

0
Today / 12:41
|
890

Biogen Stock Rises as Stifel Maintains Buy

Biogen stock rises as Stifel maintains buy rating. Updates on Alzheimer's drug trial and financial results.

0
Today / 12:32
|
422

Compass Point raises Nebius target to $260 on strong Q1

Compass Point raised Nebius price target to $260 on strong Q1 results. ARR and AI Cloud revenue surge. Read more on Bond.az.

0
Today / 11:44
|
476

H.C. Wainwright Reiterates Immunic Stock Rating

H.C. Wainwright maintains Buy rating and $22 price target on Immunic stock. The company awaits pivotal MS drug trial results. Read more on Bond.az.

0
Today / 11:43
|
800

H.C. Wainwright Reiterates Kamada Buy Rating

H.C. Wainwright reaffirms Buy rating on Kamada with $13 target. Kamada expects double-digit revenue growth in 2026.

0
Today / 11:42
|
902

Titan Mining Price Target Cut by H.C. Wainwright

H.C. Wainwright cuts Titan Mining price target to $6.50, maintains Buy. Stock up 357% in a year, but Bond.az flags overvaluation risk.

0
Today / 11:41
|
334

Avino Silver & Gold Target Raised by Analyst

H.C. Wainwright raises Avino Silver & Gold price target to $13.00 after strong earnings report with 109% revenue growth.

0
Today / 11:05
|
280

Truist reiterates Buy on Uber stock

Truist Securities reiterates Buy on Uber stock with $112 target, citing AV strength and growth potential.

0
Today / 11:04
|
241

CrowdStrike target raised to $621 by BTIG | Bond.az

BTIG raises CrowdStrike stock price target to $621, citing platform growth and partner feedback. Stock up 20% YTD.

0
Today / 11:02
|
419

Truist raises CG Oncology target to $82 on NMIBC data

Truist Securities raises CG Oncology price target to $82 from $77 on NMIBC data. Stock near 52-week high after 206% yearly gain.

0
...